Renaissance Technologies
MRNA icon

Renaissance Technologies’s Moderna MRNA Stock Holding History

Renaissance Technologies’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-881,200
Closed -$44.8M – 3479
2026
Q1 		$44.8M Buy
881,200
+312,800
+55% +$14.6M 0.07% 354
2025
Q4 		$16.8M Buy
+568,400
New +$15.4M 0.03% 685
2025
Q3 		– Sell
-1,003,900
Closed -$27.7M – 3758
2025
Q2 		$27.7M Sell
1,003,900
-356,200
-26% -$9.38M 0.04% 573
2025
Q1 		$38.6M Buy
1,360,100
+349,342
+35% +$12.4M 0.06% 405
2024
Q4 		$42M Buy
1,010,758
+700,458
+226% +$33.5M 0.06% 379
2024
Q3 		$20.7M Buy
310,300
+224,400
+261% +$20.6M 0.03% 642
2024
Q2 		$10.2M Sell
85,900
-21,900
-20% -$2.77M 0.02% 908
2024
Q1 		$11.5M Buy
+107,800
New +$10.9M 0.02% 920
2023
Q3 		– Sell
-196,699
Closed -$23.9M – 3940
2023
Q2 		$23.9M Sell
196,699
-140,013
-42% -$18.7M 0.03% 590
2023
Q1 		$51.7M Buy
336,712
+284,748
+548% +$47M 0.07% 339
2022
Q4 		$9.33M Sell
51,964
-911,077
-95% -$149M 0.01% 1119
2022
Q3 		$114M Sell
963,041
-1,221,100
-56% -$185M 0.16% 135
2022
Q2 		$312M Sell
2,184,141
-1,634,039
-43% -$234M 0.37% 48
2022
Q1 		$658M Buy
3,818,180
+1,984,458
+108% +$334M 0.77% 13
2021
Q4 		$466M Sell
1,833,722
-166,021
-8% -$48.5M 0.58% 24
2021
Q3 		$770M Sell
1,999,743
-1,188,711
-37% -$438M 0.99% 6
2021
Q2 		$749M Buy
3,188,454
+1,552,925
+95% +$278M 0.94% 8
2021
Q1 		$214M Sell
1,635,529
-117,195
-7% -$17M 0.27% 64
2020
Q4 		$183M Buy
+1,752,724
New +$177M 0.2% 95
2020
Q3 		– Sell
-315,400
Closed -$20.3M – 3564
2020
Q2 		$20.3M Buy
+315,400
New +$17.3M 0.02% 811
2019
Q3 		– Sell
-281,800
Closed -$4.13M – 3602
2019
Q2 		$4.13M Buy
+281,800
New +$6.05M ﹤0.01% 1917

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Renaissance Technologies's MRNA Position: Q2 2026 in Review

Renaissance Technologies sold out of Moderna (MRNA) in Q2 2026, closing a stake of 881,200 shares — an estimated $44.8M sold.

Renaissance Technologies first reported a position in MRNA in Q2 2019 and held it in 21 quarters. The position peaked at $770M in Q3 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Renaissance Technologies reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 881,200 Moderna shares in Q2 2026, an estimated $44.8M.
  • Renaissance Technologies first reported a position in Moderna in Q2 2019 and held it in 21 quarters.
  • Renaissance Technologies's Moderna position peaked at $770M in Q3 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.